{"id":"nph-regular-70-30-mix","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NPH (neutral protamine Hagedorn) insulin is an intermediate-acting insulin that provides sustained glucose lowering over 12-24 hours, while regular (soluble) insulin is a short-acting insulin that rapidly lowers blood glucose after meals. The 70/30 formulation delivers 70% NPH and 30% regular insulin in a single injection, allowing patients to achieve both background insulin coverage and postprandial glucose control with a fixed-ratio combination.","oneSentence":"This insulin mixture combines intermediate-acting NPH insulin with rapid-acting regular insulin to provide both basal and mealtime glucose control in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:56.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT00821795","phase":"PHASE4","title":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy","status":"COMPLETED","sponsor":"Dennis G. Karounos, M.D.","startDate":"2009-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01358435","phase":"PHASE1","title":"Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2011-01","conditions":"Diabetes Mellitus","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Novolin 70/30"],"phase":"marketed","status":"active","brandName":"NPH/Regular 70/30 mix","genericName":"NPH/Regular 70/30 mix","companyName":"Dennis G. Karounos, M.D.","companyId":"dennis-g-karounos-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NPH (Neutral Protamine Hagedorn) insulin and regular insulin are mixed in a 70/30 ratio, which is a type of insulin combination used to manage diabetes mellitus, type 2, among other conditions such as atherosclerosis, cardiovascular diseases, hypercholesterolemia, and hypertension. This insulin combination is classified as a small molecule modality, specifically used as an anti-hyperglycemic agent.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}